News | Stents | November 10, 2017

Cordis Showcases Comprehensive Interventional Cardiology Portfolio with Coronary Stents at TCT 2017

Portfolio now includes Medinol’s Tryton Side Branch Stent and NIRxcell bare metal stent


November 10, 2017 — Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now includes two coronary stents — the Tryton Side Branch Stent and Medinol’s NIRxcell, a cobalt-chromium bare metal stent (BMS). Cordis’ cardiology products were on display during the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Oct. 29-Nov. 2 in Denver.

The recent Cardinal Health agreement with Israel-based Medinol gives Cordis exclusive rights to sell Medinol’s coronary stent portfolio in the United States. Cordis is now selling Medinol’s NIRxcell BMS and, upon Medinol receiving U.S. Food and Drug Administration (FDA) approval, Cordis will also be the exclusive distributor of the EluNIR drug-eluting stent (DES). The EluNIR DES is currently an investigational device and not approved for commercial use in the U.S.

Medinol’s NIRxcell Bare-Metal Stent and EluNIR Drug-Eluting Stent are supported by a large body of clinical data, according to the company. The NIRxcell BMS has been tested on more than 1,000 patients and found highly effective in numerous clinical trials. Data from BIONICS, a global pivotal study of 1,919 patients from 76 sites in 8 countries, was submitted to the FDA to support U.S. regulatory approval of the EluNIR DES for the treatment of patients with narrowing or blockages to their coronary arteries. The EluNIR DES is currently an investigational device and not approved for commercial use in the U.S. Medinol recently received CE-mark and other regulatory clearances in Europe for the EluNIR stent.

The Tryton Side Branch Stent, the first dedicated bifurcation device to receive regulatory approval in the U.S., is approved for the treatment of de novo coronary bifurcation lesions involving large side branches (appropriate for a ≥2.5mm stent). The device is built using proprietary Tri-Zone technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt-chromium stent is deployed in the side branch artery using a standard, single-wire, balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

For more information: www.cordis.com

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now